Takashi Shinzato

Takashi Shinzato

Auto-generated profile, based on publicly available information

Takashi Shinzato

Department of General Internal Medicine, Nakagami Hospital, Okinawa, JPN

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2021 in International Journal of Infectious Diseases
Verified
Journal Article
Open access
AIAkihiro Ito
Akihiro Ito
YYYoshihiro Yamamoto
Yoshihiro Yamamoto
YIYoshikazu Ishii
Yoshikazu Ishii
AOAkihito Okazaki
Akihito Okazaki
YIYoshihisa Ishiura
Yoshihisa Ishiura
KTKazuhiro Tateda
Kazuhiro Tateda
The aim of this study was to evaluate the diagnostic utility of a novel test kit that could theoretically detect all serogroups of Legionella pneumophila for diagnosing Legionella pneumonia, in comparison with existing kits. This study was conducted in 16 hospitals in Japan from April 2016 to December 2018. Three urinary antigen test kits were used: the novel kit (LAC-116), BinaxNOW Legionella (Binax), and Q-line Kyokutou Legionella (Q-line). In addition, sputum culture and nucleic acid detection tests and serum antibody tests were performed where possible. The diagnostic accuracy and correlations of the novel kit with the two existing kits were analyzed. In total, 56 patients were diagnosed with Legionella pneumonia. The sensitivities of LAC-116, Binax, and Q-line were 79%, 84%, and 71%, respectively. The overall match rate between LAC-116 and Binax was 96.8% and between LAC-116 and Q-line was 96.4%. One patient had L. pneumophila serogroup 2, and only LAC-116 showed a positive result, whereas Binax and Q-line did not. The novel Legionella urinary antigen test kit was useful for diagnosing Legionella pneumonia. In addition, it could detect Legionella pneumonia caused by non-L. pneumophila serogroup 1.

23 September 2022 in Journal of Infection and Chemotherapy
Verified
Journal Article
Closed access
TSTakashi Shinzato
Takashi Shinzato
TYTadahiro Yonaha
Tadahiro Yonaha
YOYusuke Oshiro
Yusuke Oshiro
HIHaruka Ishiki
Haruka Ishiki

6 November 2024 in Cureus
Verified
Journal Article
Open access
PDF file
TSTakashi Shinzato
Takashi Shinzato
TYTadahiro Yonaha
Tadahiro Yonaha
We present a case of new-onset Graves' disease in a 40-year-old woman following COVID-19 infection. The patient experienced hand tremors, palpitations, shortness of breath with minimal exertion, and excessive sweating one week after recovering from COVID-19. Thyroid function tests revealed thyrotoxicosis, elevated free thyroxine, free triiodothyronine, and suppressed thyroid-stimulating hormone levels. Positive antithyroid peroxidase and thyroid-stimulating hormone (TSH) receptor antibodies, along with ultrasonography findings of diffuse thyroid enlargement and hypervascularization, confirmed the diagnosis of Graves' disease. Scintigraphy was omitted per the patient's request. This case contributes to the growing evidence suggesting SARS-CoV-2 may trigger autoimmune responses leading to thyroid disorders. We discuss the epidemiology, clinical characteristics, and potential mechanisms of Graves' disease following COVID-19, reviewing 28 similar cases reported from 2020 to early 2024. Our analysis reveals varied onset times and severity of thyroid dysfunction post-COVID-19, with some cases progressing to thyroid storm. Our findings highlight the importance of vigilant post-COVID-19 follow-up and contribute to understanding SARS-CoV-2's long-term consequences. From a cost-benefit perspective, a targeted screening approach might be needed for patients with persistent symptoms suggestive of thyroid dysfunction. This strategy could facilitate early detection and treatment, potentially preventing complications and reducing long-term healthcare costs.

11 June 2024 in Cureus
Verified
Journal Article
Open access
KSKan Sakai
Kan Sakai
TYTadahiro Yonaha
Tadahiro Yonaha
TSTakashi Shinzato
Takashi Shinzato
TTTakahiro Taira
Takahiro Taira
This case report presents a 77-year-old woman who developed subacute thyroiditis following COVID-19. The patient exhibited atypical symptoms, including fever, fatigue, anorexia, significant weight loss, headaches, and palpitations, without the typical neck pain or tenderness associated with thyroiditis. One week later, a follow-up examination showed mild enlargement and tenderness of the thyroid. Laboratory tests indicated elevated thyroid hormone levels and suppressed thyroid-stimulating hormone. Ultrasonography revealed diffuse thyroid enlargement with poor blood flow, consistent with subacute thyroiditis. Despite the absence of typical neck pain, the diagnosis was supported by clinical, laboratory, and imaging findings. This case suggests the importance of considering subacute thyroiditis as a potential secondary condition following COVID-19, even in the absence of typical symptoms. Clinicians should consider that and perform thorough evaluations in patients with recent COVID-19 exposure and nonspecific symptoms.

30 March 2025 in Diagnostic Microbiology and Infectious Disease
Verified
Journal Article
Closed access
HIHaruka Ishiki
Haruka Ishiki
YOYusuke Oshiro
Yusuke Oshiro
TSTakashi Shinzato
Takashi Shinzato
KTKenya Toma
Kenya Toma
KOKiyofumi Ohkusu
Kiyofumi Ohkusu

16 March 2026 in Cureus
Verified
Journal Article
Open access
PDF file
ANAyano Nakamura
Ayano Nakamura
KWKou Watanabe
Kou Watanabe
WSWataru Sato
Wataru Sato
KKKeito Kishimoto
Keito Kishimoto
KHKensaku Hiyajo
Kensaku Hiyajo
YTYasuharu Tokuda
Yasuharu Tokuda
Background and aims: Although guidelines recommend early biliary drainage for acute cholangitis, evidence for optimal timing across severity grades remains limited. We examined associations between drainage timing and both functional and survival outcomes stratified by disease severity using the Tokyo Guidelines 2018 criteria. Methods: This retrospective observational cohort study included 214 consecutive patients with acute cholangitis who underwent endoscopic retrograde cholangiopancreatography between April 2022 and March 2024 at a tertiary center in Okinawa, Japan. Patients were classified according to the 2018 Tokyo Guidelines severity criteria. The primary outcome was discharge disposition (favorable: discharge to pre-admission residence; unfavorable: alternative facility or death). Time from presentation to drainage was analyzed at 12-, 24-, 36-, and 48-hour cutoffs using Fisher's exact test. Results: The cohort comprised 92 Grade I (43%), 83 Grade II (39%), and 39 Grade III (18%) patients. Discharge-to-pre-admission-residence rates were 95% (87/92), 80% (66/83), and 69% (27/39), respectively. For Grade I, drainage within 24 hours was associated with 100% (59/59) discharge to pre-admission residence versus 88% (28/32) beyond 24 hours (P = 0.013). Grade II showed no functional benefit but was associated with improved survival when drainage occurred within 48 hours (99% vs 82%, P = 0.045). Grade III survivors showed better functional recovery with drainage within 24 hours (92% vs 50%, P = 0.014), though this comparison included only 10 patients in the delayed group and should be interpreted with considerable caution. Conclusions: Associations between drainage timing and outcomes varied by severity grade and outcome type. Given the observational design and limited adjustment for confounders, these findings suggest severity-stratified drainage protocols may be beneficial but require validation through prospective studies with multivariable adjustment to establish causality.